Castle Biosciences, a skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the appointment of G. Bradley Cole to its Board of Directors.
Read More
Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease
Breast Cancer Index Endorsed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update
Read More
Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced Medicare coverage for the DecisionDx®-Melanoma test that predicts risk of metastatic disease and helps to guide use of sentinel lymph node biopsy (SLNB) in patients with cutaneous melanoma.
Read More
CareMetx, a technology-enabled hub services provider for pharmaceutical and biotechnology manufacturers, today announced they have acquired VirMedica, the leader in e-access technology solutions designed to streamline patient access to life-enhancing therapies.
Read More
HealthQuest participated in a $120M Series B financing into Ajax Health, a platform company focused on investing in and accelerating innovative medical technologies that address significant unmet clinical needs.
Read More
HealthQuest Capital portfolio company Avedro, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa® drug formulations.
Read More
HealthQuest led a $25 million investment into CleanSlate, a national leader in outpatient pharmacological treatment for the chronic disease of addiction.
Read More
American Well, a leading U.S. telehealth provider, today announced that it has entered into a definitive agreement to acquire Avizia, a leading player in acute care telehealth.
Read More
HealthQuest led a $26.5 million investment into BioIQ, the leading platform for orchestrating health testing programs and biometric screening events across multiple vendors. Additionally, BioIQ utilizes multi-channel communication tools for engaging and motivating participants. HealthQuest was joined in this investment by Arboretum Ventures and select insiders.
Read More
Trice Medical completes its first successful case performed in the United Kingdom, after receiving CE Mark of approval in Europe for the mi-eye 2™, as well as entry into Health Canada.
Read More
HealthQuest Capital, EW Healthcare partners and Madryn Asset Management invested an additional $7 million in Venus Concept concurrent with the completion of the acquisition of NeoGraft. NeoGraft is an industry leader in the area of hair restoration technologies. Venus Concept's industry first and only subscription-based business model, combined with its global reach in over 60 countries and 27 direct global offices, will create a significant opportunity to expand the overall combined businesses of both NeoGraft and Venus Concept.
Read More
HealthQuest led a $20 million investment into Springbuk, the leading employer-facing health intelligence software. HealthQuest was joined in this investment by Echo Health Ventures and Lewis & Clark Ventures.
Springbuk was founded in 2015 by Rod Reasen and Phil Daniels, co-founders of the Healthiest Employers awards program, with the mission to empower employers to lower their healthcare costs by harnessing their health data. Today, over 1,000 employers use Springbuk’s software to glean actionable insights to improve their population’s health.
Read More
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-UMSeq panel that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to uveal melanoma (UM). The new test will complement Castle Biosciences’ standard-of-care DecisionDx®-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.
Read More